文档介绍：会计学
1
CCONMDPSatelliteAppelbaum异基因骨髓移植
About These Slides
Our thanks to the presenters who gave permission to include their original data
Users are encouraged to use these slides in their own noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent
These slides may not be published or posted online without permission from Clinical Care Options
Disclaimer The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
第1页/共40页
Indications for MRD HCT in AML Age < 60
PIF
Recurrent disease
CR1
第2页/共40页
Allogeneic HCT for Primary Refractory AML
Fung HC, et al. Biol Blood Marrow Transplant. 2003;9:766-770. Reproduced with permission.
第3页/共40页
URD HCT for PIF AML
N
186
Courses
Interval
mo
D100 mortality
16%
2-yr survival
31%
Multivariate ↑
short interval
good/intermediate cyto
RIC
Craddock CF, et al. ASH 2008. Abstract 564.
第4页/共40页
Management of Recurrent AML in Younger Patients
Prognosis
Breems DA, et al. J Clin Oncol. 2005;23:1969-1978. Reprinted with permission. © 2005 American Society of Clinical Oncology. All rights reserved
第5页/共40页
Management of Recurrent AML in Younger Patients
Risk Group
Treatment
5-yr Survival
Favorable
Chemo
33%
HCT
88%
Intermediate
Chemo
21%
HCT
48%
Poor risk
Chemo
6%
HCT
26%
Breems DA, et al. J Clin Oncol. 2005;23:1969-1978.
第6页/共40页
Meta-Anal